MSB 1.49% $1.02 mesoblast limited

Alzheimer drug approved, page-62

  1. 16,707 Posts.
    lightbulb Created with Sketch. 2386
    The belated long term review of one of the trials for Aducanumab DID achieve the primary end point. The major problem here is that the other trial didn't, and that's a consistency problem.

    And there is no relationship to MSB's products or trials.
    Last edited by whytee: 08/06/21
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.